专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160046959A1 REPRODUCIBLE METHOD FOR TESTIS-MEDIATED GENETIC MODIFICATION (TGM) AND SPERM-MEDIATED GENETIC MODIFICATION (SGM) 审中-公开
标题翻译：用于检测介质遗传修饰（TGM）和扩增基因修饰（SGM）的重现方法
公开(公告)号：US20160046959A1
公开(公告)日：2016-02-18
申请号：US14776656
申请日：2014-03-17
申请人： Carlisle P. LANDEL , Eric . OSTERTAG , Joseph RUIZ , Tseten YESHI , TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
发明人： Carlisle P. Landel , Eric M. Ostertag , Joseph Ruiz , Tseten Yeshi
IPC分类号： C12N15/85 , A01K67/027
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2217/05 , A01K2217/07 , A01K2217/072 , A01K2227/105 , C12N2800/40 , C12N2800/90 , C12N2999/007
摘要： The present invention provides a method of direct germline mutagenesis of a non-human animal.
摘要翻译：本发明提供了非人动物的直接种系诱变的方法。

2. 发明申请

US20160174533A1 GENETICALLY MODIFIED RAT MODELS FOR DRUG METABOLISM 审中-公开
标题翻译：用于药物代谢的遗传修饰大鼠模型
公开(公告)号：US20160174533A1
公开(公告)日：2016-06-23
申请号：US15040254
申请日：2016-02-10
申请人： Transposagen Biopharmaceuticals, Inc.
发明人： Eric M. Ostertag , John Stuart Crawford
IPC分类号： A01K67/027
CPC分类号： A01K67/0276 , A01K2207/05 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/03 , C07K14/705 , C12N15/8509 , C12N2800/90 , G01N33/94 , G01N2500/04 , G01N2500/10
摘要： The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to alterations in drug and chemical metabolism by modification of its structure or mechanism. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug metabolism gene such as the Cyp7b1 gene, the Cyp3a4 gene, etc. In another embodiment, the rat cell is a somatic cell. The inactivation of at least one drug metabolism allele results in an animal with a higher susceptibility to altered drug and chemical metabolism. In one embodiment, the genetically altered animal is a rat of this type and is able to serve as a useful model for altered drug and chemical metabolism or toxicology and as a test animal for autoimmune and other studies. The invention additionally pertains to the use of such rats or rat cells, and their progeny in research and medicine. In one embodiment, the invention provides a genetically modified or chimeric rat cell whose genome comprises two chromosomal alleles of a drug metabolism gene wherein at least one of the two alleles contains a mutation, or the progeny of the cell.
摘要翻译：本发明提供了期望的大鼠或大鼠细胞，其包含预定义的特异性和期望的改变，使得大鼠或大鼠细胞易于改变其结构或机制而改变药物和化学代谢。具体地说，本发明涉及在诸如Cyp7b1基因，Cyp3a4基因等药物代谢基因的两个等位基因中的至少一个中缺失的基因改变的大鼠或培养物中的大鼠细胞。在另一个实施方案中，大鼠细胞是体细胞。至少一种药物代谢等位基因的失活导致对改变的药物和化学代谢具有较高敏感性的动物。在一个实施方案中，遗传改变的动物是这种类型的大鼠，并且能够用作改变的药物和化学代谢或毒理学的有用模型，并且作为用于自身免疫和其他研究的测试动物。本发明还涉及这些大鼠或大鼠细胞及其后代在研究和医学中的应用。在一个实施方案中，本发明提供了遗传修饰或嵌合的大鼠细胞，其基因组包含药物代谢基因的两个染色体等位基因，其中两个等位基因中的至少一个含有突变或细胞的后代。

3. 发明申请

US20150052624A1 GENETICALLY MODIFIED RAT MODELS FOR PAIN 审中-公开
标题翻译：用于疼痛的遗传修饰大鼠模型
公开(公告)号：US20150052624A1
公开(公告)日：2015-02-19
申请号：US14502775
申请日：2014-09-30
申请人： Transposagen Biopharmaceuticals, Inc.
发明人： Eric M. Ostertag , John Stuart Crawford , Karin Westlund High
IPC分类号： A01K67/027 , G01N33/94 , A61K49/00 , C12N15/85 , G01N33/50
CPC分类号： A01K67/0276 , A01K2207/05 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/0356 , A61K49/0008 , C12N15/8509 , C12N2800/90 , G01N33/5088 , G01N33/9486 , G01N2333/705 , G01N2500/10
摘要： This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal. In another aspect, the nervous system dysfunction results in prolonged hyperalgesia, allodynia, and loss of sensory function. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of altered nervous system function mediated pain and methods of their use. In another aspect, the genetically modified rats, as well as the descendants and ancestors of such animals, are animal models of nervous system dysfunction resulting in prolonged hyperalgesia, allodynia, and loss of sensory function and methods of their use. In another aspect, the present invention provides a method of identifying a compound useful for the treatment or prevention of pain.
摘要翻译：本发明涉及由于导致神经系统功能改变的基因或基因产物的破坏而缺乏的动物细胞，优选哺乳动物，更优选的大鼠的工程。在一个方面，改变的功能导致哺乳动物的疼痛。另一方面，神经系统功能障碍导致持续的痛觉过敏，异常性疼痛和感觉功能丧失。另一方面，本发明涉及遗传修饰的大鼠，以及这些动物的后代和祖先，其是改变的神经系统功能介导的疼痛的动物模型及其使用方法。另一方面，遗传修饰的大鼠以及这些动物的后裔和祖先是神经系统功能障碍的动物模型，导致持续的痛觉过敏，异常性疼痛和感觉功能丧失及其使用方法。另一方面，本发明提供鉴定可用于治疗或预防疼痛的化合物的方法。

4. 发明申请

US20180295819A1 GENETICALLY MODIFIED RAT MODELS FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID) 审中-公开
公开(公告)号：US20180295819A1
公开(公告)日：2018-10-18
申请号：US15810272
申请日：2017-11-13
申请人： Transposagen Biopharmaceuticals, Inc.
发明人： Eric M. Ostertag , John Stuart Crawford , Joseph Ruiz
IPC分类号： A01K67/027 , C12N15/90 , C12N15/87 , C12N15/85 , C12N9/22 , C12N9/14 , C12N9/12
摘要： This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

5. 发明申请

US20160174534A1 GENETICALLY MODIFIED RAT MODELS FOR PHARMACOKINETICS 审中-公开
公开(公告)号：US20160174534A1
公开(公告)日：2016-06-23
申请号：US14979754
申请日：2015-12-28
申请人： Transposagen Biopharmaceuticals, Inc.
发明人： Eric M. Ostertag , John Stuart Crawford
IPC分类号： A01K67/027
CPC分类号： A01K67/0278 , A01K67/0271 , A01K67/0276 , A01K2207/05 , A01K2207/12 , A01K2207/15 , A01K2207/20 , A01K2217/052 , A01K2217/075 , A01K2217/15 , A01K2227/10 , A01K2227/105 , A01K2267/03 , A01K2267/0306 , C07K14/705 , C12N15/8509 , C12N2800/90 , G01N33/5088 , G01N33/94 , G01N2500/04 , G01N2500/10
摘要： The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the Slc7a11 (NC_005101.2) gene, the Abcb1 (NC_005103.2) gene, etc. The present invention also provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene.

6. 发明申请

US20160174532A1 GENETICALLY MODIFIED RAT MODELS FOR PAIN 审中-公开
公开(公告)号：US20160174532A1
公开(公告)日：2016-06-23
申请号：US14979760
申请日：2015-12-28
申请人： Transposagen Biopharmaceuticals, Inc.
发明人： Eric M. Ostertag , John Stuart Crawford , Karin Westlund High
IPC分类号： A01K67/027
CPC分类号： A01K67/0276 , A01K2207/05 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/0356 , A61K49/0008 , C12N15/8509 , C12N2800/90 , G01N33/5088 , G01N33/9486 , G01N2333/705 , G01N2500/10
摘要： This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal. In another aspect, the nervous system dysfunction results in prolonged hyperalgesia, allodynia, and loss of sensory function. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of altered nervous system function mediated pain and methods of their use. In another aspect, the genetically modified rats, as well as the descendants and ancestors of such animals, are animal models of nervous system dysfunction resulting in prolonged hyperalgesia, allodynia, and loss of sensory function and methods of their use. In another aspect, the present invention provides a method of identifying a compound useful for the treatment or prevention of pain.

7. 发明申请

US20160060610A1 Site-Specific Enzymes And Methods Of Use 审中-公开
标题翻译：位点特异性酶和使用方法
公开(公告)号：US20160060610A1
公开(公告)日：2016-03-03
申请号：US14443361
申请日：2013-11-18
申请人： TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
发明人： Eric M. Ostertag , Tseten Yeshi
IPC分类号： C12N9/22
摘要： The present invention provides polypeptides related to Ralstonia proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
摘要翻译：本发明提供了与拉尔斯通氏蛋白相关的多肽，编码该核酸的组合物，包含该多肽的组合物，包含该多肽的非人转基因动物的试剂盒及其使用方法。

8. 发明申请

US20140329856A1 METHOD OF TREATING PAIN 审中-公开
标题翻译：治疗疼痛的方法
公开(公告)号：US20140329856A1
公开(公告)日：2014-11-06
申请号：US14303711
申请日：2014-06-13
申请人： Transposagen Biopharmaceuticals, Inc.
发明人： Eric M. Ostertag , John Stuart Crawford
IPC分类号： C07D215/38 , A61K45/06 , A61K31/4709
CPC分类号： C07D215/38 , A61K31/00 , A61K31/4709 , A61K45/06
摘要： The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the TRP channel may be TRPC4. Types of pain contemplated by the present disclosure include acute, chronic, neuropathic, and nociceptive pain.
摘要翻译：本申请公开了治疗，减轻或预防哺乳动物疼痛的方法，其可包括施用能够调节瞬时受体潜能通道的化合物。一方面，TRP信道可以是TRPC4。本公开所涵盖的疼痛类型包括急性，慢性，神经性疼痛和伤害性疼痛。

9. 发明申请

US20160302397A1 GENETICALLY MODIFIED RAT MODELS FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID) 审中-公开
标题翻译：用于严重组合免疫球蛋白（SCID）的遗传修饰大鼠模型
公开(公告)号：US20160302397A1
公开(公告)日：2016-10-20
申请号：US15070275
申请日：2016-03-15
申请人： Transposagen Biopharmaceuticals, Inc.
发明人： Eric M. Ostertag , John Stuart Crawford , Joseph Ruiz
IPC分类号： A01K67/027 , C12N15/85
CPC分类号： A01K67/0276 , A01K2217/054 , A01K2217/056 , A01K2217/15 , A01K2217/20 , A01K2217/206 , A01K2227/105 , A01K2267/0331 , A01K2267/0387 , C12N9/1205 , C12N9/14 , C12N9/22 , C12N15/8509 , C12N15/87 , C12N15/907 , C12N2015/8536
摘要： This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
摘要翻译：本发明涉及由于肿瘤抑制基因或基因产物的破坏而缺乏的动物细胞，优选哺乳动物，更优选的大鼠的工程。另一方面，本发明涉及基因修饰的大鼠，以及这些动物的后裔和祖先，它们是人类癌症的动物模型及其使用方法。

10. 发明申请

US20140041063A1 Genetically Modified Rat Models for Obesity and Diabetes 审中-公开
标题翻译：遗传修饰的肥胖和糖尿病大鼠模型
公开(公告)号：US20140041063A1
公开(公告)日：2014-02-06
申请号：US14017762
申请日：2013-09-04
申请人： Transposagen Biopharmaceuticals, Inc.
发明人： Eric M. Ostertag , John Stuart Crawford , Edwin Cuppen
IPC分类号： A61K49/00
CPC分类号： A61K49/0008 , A01K67/0271 , A01K67/0276 , A01K2217/05 , A01K2227/105 , A01K2267/0362 , C07K14/715 , C07K14/723 , C12N2800/90 , G01N2800/042 , G01N2800/044
摘要： This invention relates to a genetically modified or chimeric rat cell whose genome comprises chromosomal alleles of an obesity-diabetes gene (especially, the Mc4r gene or Lep gene), wherein at least one of the two alleles contains a mutation, or the progeny of this cell. The obesity or diabetes gene may affect any of the pathways of obesity and diabetes. The obesity or diabetes gene may predispose the rat to a phenotype of obese and diabetic, lean and diabetic, obese and non-diabetic, non-obese and diabetic or any of the combinations thereof. In another aspect, the invention relates to a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to obesity or diabetes.
摘要翻译：本发明涉及遗传修饰或嵌合大鼠细胞，其基因组包含肥胖 - 糖尿病基因的染色体等位基因（特别是Mc4r基因或Lep基因），其中两个等位基因中的至少一个含有突变，或该后代细胞。肥胖症或糖尿病基因可能会影响肥胖和糖尿病的任何途径。肥胖症或糖尿病基因可能将大鼠倾向于肥胖和糖尿病，贫血和糖尿病，肥胖和非糖尿病，非肥胖和糖尿病或其任何组合的表型。在另一方面，本发明涉及期望的大鼠或大鼠细胞，其含有预期的特异性和期望的改变，使大鼠或大鼠细胞倾向于肥胖或糖尿病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式